Equities

Aqua Bio Technology ASA

Aqua Bio Technology ASA

Actions
  • Price (NOK)4.65
  • Today's Change0.00 / 0.00%
  • Shares traded1.90k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of Feb 14 2024 17:15 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aqua Bio Technology ASA is a Norway-based skincare company. The Company develops and commercializes sustainable biotechnology for use in skin care products. ABT develops new active ingredients for skincare based on marine technology with documented positive effects on human skin. The ingredients are based on natural and sustainable substances, found in plants, algae and in the oceans and provide the cosmetics industry with natural alternatives to traditional ingredients. In addition to ingredients from its own technology, ABT also markets and distributes natural skincare products to consumers, retailers and professional users in Europe and the Middle East. The ABT portfolio of skincare products contains exclusive and high-end products as well as off the shelf products. They are distributed over the Internet, in stores and through professional channels such as skincare clinics.

  • Revenue in NOK (TTM)13.51m
  • Net income in NOK-1.50m
  • Incorporated2004
  • Employees2.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ABTEC:OSL since
announced
Transaction
value
Ovalen AsAnnounced08 Feb 202408 Feb 2024Announced-10.87%1.04m
Cover Brands ASDeal completed19 Dec 202319 Dec 2023Deal completed78.97%1.46m
Skinteam Norge ASDeal completed23 Jul 202323 Jul 2023Deal completed58.25%4.47m
Data delayed at least 15 minutes, as of May 03 2024.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.